Delving into the Latest Updates on D-314 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target

Mechanism

GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2Obesity

Inactive Indication-

Originator Organization

Shanghai Duomirui Biotechnology Co., Ltd.

Active Organization

Shanghai Duomirui Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

OBJECTIVESRelapsed/refractory acute B-cell lymphoblastic leukemia (R/R B-ALL) often responds poorly to induction chemotherapy. However, recent research has shown a novel and effective drug treatment for R/R B-ALL.METHODSA total of eight patients with R/R B-ALL were enrolled in the study from November 2021 to August 2022. All patients received chemotherapy based on a combination regimen of venetoclax and azacitidine. The regimen was as follows venetoclax 100 mg d₁, 200 mg d₂, 400 mg d_3-14, azacitidine 75 mg/m² d_1-7.RESULTSFive of eight patients achieved very deep and complete remission (CR) with minimal residual disease (MRD) less than 0.1%. One patient achieved partial remission. Two patients did not achieve remission. There were no serious adverse events and all patients were well tolerated. Three patients were eligible for consolidation chemotherapy and were bridged to CAR-T therapy.CONCLUSIONSThe combined regimen of venetoclax and azacitidine may be beneficial for patients with R/R B-ALL.

100 Deals associated with D-314

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Preclinical	CN	Shanghai Duomirui Biotechnology Co., Ltd.	15 Feb 2024
Obesity	Preclinical	CN	Shanghai Duomirui Biotechnology Co., Ltd.	15 Feb 2024